Cabio Biotech (Wuhan) Future Growth

Future criteria checks 5/6

Cabio Biotech (Wuhan) wird ein jährliches Wachstum der Erträge und Einnahmen um 27.2% bzw. 25.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich grow um 27.6% pro Jahr steigen. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 8.9% betragen.

Key information

27.9%

Earnings growth rate

26.7%

EPS growth rate

Chemicals earnings growth	35.1%
Revenue growth rate	26.5%
Future return on equity	9.0%
Analyst coverage	Low
Last updated	23 Mar 2024

Recent future growth updates

Recent updates

The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Mar 21

Earnings and Revenue Growth Forecasts

SHSE:688089 - Analysts future estimates and past financials data (CNY Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2025	757	160	N/A	N/A	3
12/31/2024	562	117	N/A	N/A	1
12/31/2023	445	92	N/A	N/A	N/A
9/30/2023	485	47	-178	118	N/A
6/30/2023	461	49	-150	106	N/A
3/31/2023	446	55	-126	107	N/A
12/31/2022	433	64	-73	176	N/A
9/30/2022	374	105	-104	133	N/A
6/30/2022	359	111	-96	153	N/A
3/31/2022	348	118	-66	177	N/A
12/31/2021	351	129	-70	103	N/A
9/30/2021	337	121	-34	84	N/A
6/30/2021	336	127	24	98	N/A
3/31/2021	347	139	36	78	N/A
12/31/2020	323	131	113	146	N/A
9/30/2020	317	132	152	174	N/A
6/30/2020	315	126	147	161	N/A
3/31/2020	301	121	145	165	N/A
12/31/2019	312	118	109	132	N/A
9/30/2019	318	128	89	119	N/A
12/31/2018	286	97	94	106	N/A
12/31/2017	229	66	78	101	N/A
12/31/2016	190	47	N/A	63	N/A
12/31/2015	181	20	N/A	45	N/A
12/31/2014	187	38	N/A	46	N/A
12/31/2013	200	47	N/A	39	N/A

Analyst Future Growth Forecasts

Einkommen vs. Sparrate: 688089Das prognostizierte Gewinnwachstum (27.2% pro Jahr) liegt über der Sparquote (2.9%).

Ertrag vs. Markt: 688089Die Erträge des Unternehmens (27.9% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (26.4% pro Jahr).

Hohe Wachstumserträge: 688089Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: 688089Die Einnahmen des Unternehmens (25.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt CN (15.3% pro Jahr).

Hohe Wachstumseinnahmen: 688089Die Einnahmen des Unternehmens (25.4% pro Jahr) werden voraussichtlich schneller wachsen als 20% pro Jahr.

Earnings per Share Growth Forecasts

Future Return on Equity

Künftige Eigenkapitalrendite: 688089Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (8.9%).

Discover growth companies

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Cabio Biotech (Wuhan) Future Growth

Future criteria checks 5/6

Key information

Recent future growth updates

Price target decreased by 16% to CN¥30.00

Price target increased by 11% to CN¥56.50

Recent updates

Cabio Biotech (Wuhan) Co., Ltd. to Report Q1, 2024 Results on Apr 27, 2024

The Market Lifts Cabio Biotech (Wuhan) Co., Ltd. (SHSE:688089) Shares 27% But It Can Do More

Full year 2023 earnings: EPS and revenues miss analyst expectations

New major risk - Revenue and earnings growth

Investor sentiment deteriorates as stock falls 20%

Cabio Biotech (Wuhan) Co., Ltd. to Report Fiscal Year 2023 Results on Apr 27, 2024

Price target decreased by 16% to CN¥30.00

Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.17 in 2Q 2022)

Cabio Biotech (Wuhan) Co., Ltd. Showcases the New Products and Ready-To-Market Solutions At Vitafoods Europe 2023

Investor sentiment deteriorates as stock falls 15%

Full year 2022 earnings: EPS misses analyst expectations

Investor sentiment deteriorates as stock falls 15%

Price target increased by 11% to CN¥56.50

Full year 2022 earnings released: EPS: CN¥0.90 (vs CN¥1.07 in FY 2021)

Investor sentiment improved over the past week

No independent directors

Investor sentiment improved over the past week

Third quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.28 in 3Q 2021)

Investor sentiment deteriorated over the past week

Second quarter 2022 earnings released: EPS: CN¥0.23 (vs CN¥0.28 in 2Q 2021)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues miss analyst expectations

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.32 in 3Q 2020)

Investor sentiment improved over the past week

Second quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.38 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

First quarter 2021 earnings released: EPS CN¥0.28 (vs CN¥0.21 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.09 (vs CN¥1.31 in FY 2019)

Investor sentiment improved over the past week

CABIO Biotech(Wuhan) Co., Ltd. to Report Fiscal Year 2020 Results on Mar 30, 2021

CABIO Biotech(Wuhan) Co., Ltd. (SHSE:688089) entered into an agreement to acquire 11% stake in Zhongke Optics Valley Green Biotechnology Co., Ltd. from Hefei Kejv Hi-tech Co., Ltd. for CNY 10.7 million.

New 90-day low: CN¥34.84

Investor sentiment deteriorated over the past week

New 90-day low: CN¥38.96

New 90-day low: CN¥44.46

New 90-day low: CN¥46.67

First half earnings released

New 90-day high - CN¥59.42

CABIO Biotech(Wuhan) Co., Ltd. to Report First Half, 2020 Results on Aug 26, 2020

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies